These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17416108)

  • 1. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration.
    Conil JM; Georges B; Fourcade O; Seguin T; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Mar; 45(3):133-42. PubMed ID: 17416108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
    Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
    Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
    Georges B; Conil JM; Ruiz S; Seguin T; Cougot P; Fourcade O; Houin G; Saivin S
    Br J Clin Pharmacol; 2012 Apr; 73(4):588-96. PubMed ID: 21988468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
    Conil JM; Georges B; Lavit M; Laguerre J; Samii K; Houin G; Saivin S
    Br J Clin Pharmacol; 2007 Jul; 64(1):27-35. PubMed ID: 17324245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.
    Walstad RA; Aanderud L; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(5):543-9. PubMed ID: 3069478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.
    Berkhout J; Visser LG; van den Broek PJ; van de Klundert JA; Mattie H
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1862-6. PubMed ID: 12760859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections.
    Buijk SL; Gyssens IC; Mouton JW; Van Vliet A; Verbrugh HA; Bruining HA
    J Antimicrob Chemother; 2002 Jan; 49(1):121-8. PubMed ID: 11751775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.
    Georges B; Conil JM; Seguin T; Ruiz S; Minville V; Cougot P; Decun JF; Gonzalez H; Houin G; Fourcade O; Saivin S
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4483-9. PubMed ID: 19635962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.
    Girardi C; Tonnellier M; Goldstein I; Sartorius A; Wallet F; Rouby JJ;
    Intensive Care Med; 2006 Dec; 32(12):2042-8. PubMed ID: 16858611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
    Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of ceftazidime with an elastomeric infusion device.
    Couldry R; Sanborn M; Klutman NE; Strayer AH
    Am J Health Syst Pharm; 1998 Jan; 55(2):145-9. PubMed ID: 9465978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of ceftazidime in burn patients.
    Dailly E; Pannier M; Jolliet P; Bourin M
    Br J Clin Pharmacol; 2003 Dec; 56(6):629-34. PubMed ID: 14616422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age.
    van den Anker JN; Schoemaker RC; Hop WC; van der Heijden BJ; Weber A; Sauer PJ; Neijens HJ; de Groot R
    Clin Pharmacol Ther; 1995 Dec; 58(6):650-9. PubMed ID: 8529330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime in the elderly: appropriateness of twice-daily dosing.
    Sirgo MA; Norris S
    DICP; 1991 Mar; 25(3):284-8. PubMed ID: 2028636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis.
    König C; Braune S; Roberts JA; Nierhaus A; Steinmetz OM; Baehr M; Frey OR; Langebrake C; Kluge S
    J Antimicrob Chemother; 2017 May; 72(5):1433-1440. PubMed ID: 28175308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.